Homepage Top Section2

The formulation will serve as a new administration route. Eisai’s application is based on data from several SC administration sub-studies of lecanemab, conducted within the Phase III Clarity

Cellergy will utilise the good manufacturing practices (GMP) expertise of Made Scientific to enhance its mitochondrial isolation and purification process for the clinical-grade production of CLG-001. This work

The investment covers both expansion of the Frederick biologics manufacturing facility and a new plant construction in Gaithersburg, targeting operational readiness by 2029. The Frederick site, which produces

This round will also bolster the company’s manufacturing offerings and support additional pipeline therapies. It was jointly led by OrbiMed, Frazier Life Sciences, ARCH Venture Partners and Revelation

The protection for this patent will last until 2037. Genprex has also obtained similar patent protection for the gene therapy used with PD-L1 antibodies in Korea, and is

Leqembi is a humanised anti-soluble aggregated amyloid-beta monoclonal antibody. The development follows the August 2024 approval for treating mild cognitive impairment (MCI) and mild dementia caused by Alzheimer’s

This collaboration is intended for the development of advanced biological signatures to improve targeted treatment strategies. It centres on leveraging BostonGene’s AI-powered omnimodal platform to analyse tumour molecular

The RMAT designation was based on initial data from March Bio’s ongoing multi-centre Phase II clinical trial, which indicated clinical activity and a manageable safety profile in a

The new site increases capacity and strengthens the company’s supply chain capabilities for RLTs in the US. The facility in Carlsbad, filed with the US Food and Drug